132
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Hyperthermic enhancement of tumour growth inhibition by accelerated carbon-ions in transplantable human esophageal cancer

, , , , , , , , & show all
Pages 195-202 | Received 12 Nov 1997, Accepted 13 Nov 1997, Published online: 09 Jul 2009
 

Abstract

The study examined the effects of combination of hyperthermia (42d`C) and 290MeV/u carbon-ion (C—) beams or 200 kVp X-rays on tumour regrowth delay of transplantable human esophageal cancer as an in vivo model for radiotherapy of cancer. The C-beams were more effective in the tumour growth inhibition than X-rays. The relative biological effectiveness (RBE) of C-beams against X-rays was 2.00. It was observed that the interactive hyperthermic (42d`C, for 30 min) enhancement of tumour regrowth delay by high—linear energy transfer (LET) C-beams was similar to that of combination of low—LET X-rays with hyperthermia. The thermal enhancement ratios (TER) were 6.10 and 5.57 for X-rays and C-beams, respectively. These results suggest that hyperthermic treatment is effective in radiotherapy not only by low-LET radiation but also by high—LET radiation such as C-beams. In conclusion, the depression of the tumour growth by the combined treatment of hyperthermia (42d`C) and the C-beams strongly suggests the available possible application of interdisciplinary cancer therapy for refractory tumours.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.